Previous Close | 67.81 |
Open | 67.75 |
Bid | 67.58 x 1000 |
Ask | 67.55 x 800 |
Day's Range | 67.75 - 68.29 |
52 Week Range | 47.59 - 69.68 |
Volume | |
Avg. Volume | 1,274,943 |
Market Cap | 3.481B |
Beta (5Y Monthly) | 0.56 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.12 |
Earnings Date | Apr 29, 2024 - May 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 71.73 |
Subscribe to Yahoo Finance Plus to view Fair Value for AXNX
IRVINE, Calif., March 14, 2024--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.
Axonics ( NASDAQ:AXNX ) Full Year 2023 Results Key Financial Results Revenue: US$366.4m (up 34% from FY 2022). Net...
IRVINE, Calif., February 29, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a "patient programmer with automated MRI compatibility verification" for an implantable medical device.